349 related articles for article (PubMed ID: 11083321)
1. Clinical characteristics and prognosis of myasthenia gravis in older people.
Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
[TBL] [Abstract][Full Text] [Related]
2. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
3. High-dose immunosuppressive therapy in generalised myasthenia gravis--a 2-year follow-up study.
Heckmann JM; LeePan EB; Eastman RW
S Afr Med J; 2001 Sep; 91(9):765-70. PubMed ID: 11680327
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive therapies in myasthenia gravis.
Sanders DB; Evoli A
Autoimmunity; 2010 Aug; 43(5-6):428-35. PubMed ID: 20166870
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis.
Bromberg MB; Wald JJ; Forshew DA; Feldman EL; Albers JW
J Neurol Sci; 1997 Sep; 150(1):59-62. PubMed ID: 9260858
[TBL] [Abstract][Full Text] [Related]
6. Myasthenia gravis in children: a longitudinal study.
Ashraf VV; Taly AB; Veerendrakumar M; Rao S
Acta Neurol Scand; 2006 Aug; 114(2):119-23. PubMed ID: 16867035
[TBL] [Abstract][Full Text] [Related]
7. Long-term prednisone followed by thymectomy in myasthenia gravis.
Mann JD; Johns TR; Campa JF; Muller WH
Ann N Y Acad Sci; 1976; 274():608-22. PubMed ID: 1066998
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing the relapse risk at steroid dose reduction in myasthenia gravis.
Scherpbier HJ; Oosterhuis HJ
Clin Neurol Neurosurg; 1987; 89(3):145-50. PubMed ID: 3665287
[TBL] [Abstract][Full Text] [Related]
9. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive treatment for juvenile myasthenia gravis.
Badurska B; Ryniewicz B; Strugalska H
Eur J Pediatr; 1992 Mar; 151(3):215-7. PubMed ID: 1601015
[TBL] [Abstract][Full Text] [Related]
11. Plasmaexchange in the treatment of myasthenia gravis associated with thymoma.
Gogovska L; Ljapcev R; Polenakovic M; Stojkovski L; Popovska M; Grcevska L
Int J Artif Organs; 2003 Feb; 26(2):170-3. PubMed ID: 12653352
[TBL] [Abstract][Full Text] [Related]
12. Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients.
Lindner A; Schalke B; Toyka KV
J Neurol; 1997 Aug; 244(8):515-20. PubMed ID: 9309559
[TBL] [Abstract][Full Text] [Related]
13. Myasthenia gravis: how to treat?
Tireli H; Karlikaya G; Tutkavul K; Akpinar A; Okay T
Acta Myol; 2004 Dec; 23(3):140-5. PubMed ID: 15938570
[TBL] [Abstract][Full Text] [Related]
14. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients.
Beekman R; Kuks JB; Oosterhuis HJ
J Neurol; 1997 Feb; 244(2):112-8. PubMed ID: 9120493
[TBL] [Abstract][Full Text] [Related]
15. Randomized Trial of Thymectomy in Myasthenia Gravis.
Wolfe GI; Kaminski HJ; Aban IB; Minisman G; Kuo HC; Marx A; Ströbel P; Mazia C; Oger J; Cea JG; Heckmann JM; Evoli A; Nix W; Ciafaloni E; Antonini G; Witoonpanich R; King JO; Beydoun SR; Chalk CH; Barboi AC; Amato AA; Shaibani AI; Katirji B; Lecky BR; Buckley C; Vincent A; Dias-Tosta E; Yoshikawa H; Waddington-Cruz M; Pulley MT; Rivner MH; Kostera-Pruszczyk A; Pascuzzi RM; Jackson CE; Garcia Ramos GS; Verschuuren JJ; Massey JM; Kissel JT; Werneck LC; Benatar M; Barohn RJ; Tandan R; Mozaffar T; Conwit R; Odenkirchen J; Sonett JR; Jaretzki A; Newsom-Davis J; Cutter GR;
N Engl J Med; 2016 Aug; 375(6):511-22. PubMed ID: 27509100
[TBL] [Abstract][Full Text] [Related]
16. Transsternal thymectomy for myasthenia gravis: surgical outcome.
Kattach H; Anastasiadis K; Cleuziou J; Buckley C; Shine B; Pillai R; Ratnatunga C
Ann Thorac Surg; 2006 Jan; 81(1):305-8. PubMed ID: 16368387
[TBL] [Abstract][Full Text] [Related]
17. The effect of prednisone on the progression from ocular to generalized myasthenia gravis.
Monsul NT; Patwa HS; Knorr AM; Lesser RL; Goldstein JM
J Neurol Sci; 2004 Feb; 217(2):131-3. PubMed ID: 14706214
[TBL] [Abstract][Full Text] [Related]
18. [Ocular myasthenia: clinical course and strategies for treatment].
Marzo ME; Pérez López-Fraile I; Capablo JL; Ara JR; Usón M
Rev Neurol; 1998 Mar; 26(151):398-400. PubMed ID: 9585951
[TBL] [Abstract][Full Text] [Related]
19. [Thymectomy and immunosuppression in myasthenia gravis: a prospective study].
Sandmann MC; Gorz AM; Gracia CM; Batista RJ; Seixas RR; Bittencourt PR
Arq Neuropsiquiatr; 1990 Mar; 48(1):44-8. PubMed ID: 2378574
[TBL] [Abstract][Full Text] [Related]
20. Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Gamez J; Armengol M
Curr Med Res Opin; 2006 May; 22(5):885-95. PubMed ID: 16709310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
